RxDoctor Payments Data

Farah Alvi, PA

Medical · Baltimore, MDNPI 1316345895

Payments from drug & device makers

$2,189in general payments, 2019–2025

Across 84 payments — averaging $26.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Collegium Pharmaceutical, Inc.$513
  • Abbott$262
  • Averitas Pharma Inc.$169
  • Nevro Corp.$167
  • Saluda Medical Americas, Inc.$144
  • Medtronic$99
  • plus $835 from 16 others

What the payments were for

  • Food & beverage$2,189100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,189 in reported general payments places this provider in the 75th percentile of 543 medical providers in Maryland.

See all medical providers in Maryland

Medicare billing

Part B allowed, 2024
$196,034
Medicare patients
377
Services billed
2,069

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone Hcl886$17,812
Xtampza ErOxycodone Myristate26$12,352
OxycontinOxycodone Hcl29$9,255
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen380$8,919
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen303$7,985
Gabapentin463$6,087
Morphine Sulfate ErMorphine Sulfate247$5,649
MovantikNaloxegol Oxalate12$4,885
Pregabalin177$3,995
Oxymorphone Hcl ErOxymorphone Hcl12$3,705
Fentanyl45$2,990
Cyclobenzaprine Hcl191$2,554
Duloxetine Hcl73$1,822
Tramadol Hcl ErTramadol Hcl38$1,698
Baclofen129$1,473

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$513$12,35226 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 543 medical providers in Maryland.

Other medical in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →